We were asked by the editors of this fine journal to write a review of our work through the years using herpes simplex viral (HSV) vectors for pain gene therapy. This work began in 1997, when SPW spent a year in the laboratory of Dr Joseph Glorioso at the University of Pittsburgh learning how to make herpes vectors. There, he developed an attenuated, cytomegalovirus-promoted HSV vector encoding human preproenkephalin, precursor of the endogenous analgesic opiate peptides, leu-and met-enkephalin ( Figure 1 ).
Human preproenkephalin vector
Returning from Pittsburgh, SPW wondered whether these vectors might have potential in attenuating pain, and so contacted DCY, an opiate pain pharmacologist. Not surprisingly, DCY's initial response was somewhat skeptical as the idea of gene therapy for pain was novel at the time. However, SPW convinced DCY to come out to Columbia, South Carolina, to test the concept. This conceived scenario used the natural propensity of the herpes virus to enter the peripheral endings of painsensing neurons (nociceptors) and transport axially to the nucleus of the dorsal root ganglia cell bodies of those neurons, bringing the transgene along for the ride.
If the concept worked, the transgene would use the transcription machinery of the neuron to express the precursor protein. If the precursor were synthesized, would it be packaged in vesicles, as would a typical precursor for a peptide neurotransmitter native to these cells such as substance P? Would it be processed to form the active peptides? What would happen then? Would the peptide be released, as would an endogenous peptide neurotransmitter? Under what circumstances would it be released-evoked or constitutive? Would the peptide act at opiate receptors on the nociceptors themselves-cells that are normally inhibited by exogenous opiates and opioids?
Not surprisingly, the first experiments were unsuccessful. For these experiments, we applied the virus to the abraded dorsal surface of a mouse's paw. The idea of the abrasion was to remove the outermost epidermal barrier to viral access to the innervating nociceptor endings (nociceptors are the only sensory fibers that innervate the epidermis). The viral solution (20 ml) was then applied to the surface of the hindpaw in a concentration of 10 7 PFU ml and spread with a pipette tip. The solution was allowed to dry and the mouse was returned to their home cage. Starting 2 days later, we started measuring responses to noxious heating of the hindpaw to determine whether, and to what extent, the virus would affect responsivity. It did not-at least not significantly. We then hit on the idea that perhaps the effect might be antihyperalgesic, rather than analgesic. That is, the vector might reduce hypersensitive responses back to normal. Thus, we tried a similar experiment, except that this time we tried pretreating the skin with capsaicinthe component of hot peppers that make them hot-to sensitize the nociceptors innervating the epidermis to heat stimulation. 1 Repeating the experiment, we found that the vector treatment produced a robust antihyperalgesia, reversing the sensitizing effects of capsaicin. These effects held up for at least 7 weeks after infection. As numerous clinical pain states are characterized by hyperalgesia and allodynia, these results were most encouraging. In addition, we found that systemic injection of the opiate receptor blocker naloxone completely reversed the antihyperalgesia, indicating that this effect was specific to interactions with opiate receptors, suggesting an effect of the enkephalin peptide. Using a human specific anti-proenkephalin antibody, we were also able to show proenkephalin expression in mouse sensory neurons, and that this labeling was regionally specific. This last point was critical in that it implied that the vector was not spreading-that it was only infecting neurons in the area on which it was applied.
The nociception in the model used in our first study, however, was transient-the topical capsaicin caused the animal to be in a hyperalgesic state for several hours at most. If the approach was to eventually be used in humans, we needed to test efficacy in a more chronic state. To this end, we decided to perform experiments using a model that produces weeks-long thermal hyperalgesia. 2 This model involves intrathecal injection of pertussis toxin, which decouples (by ribosylation) certain G-proteins from inhibitory neurotransmitter receptors-effectively producing a state of chronic disinhibition of spinal neurons, exhibited by a pronounced increase in responsivity to noxious stimulation. Application of the HSV-enkephalin vector to the skin of mice that were also receiving intrathecal injections of pertussis toxin completely reversed the thermal hyperalgesia normally seen in this model, whereas a control vector, encoding b-galactosidase, did not. As in the previous study, the antihyperalgesic effect was reversed by opiate receptor-specific antagonists. Immunoreactivity to the enkephalin gene product was observed, this time in the cell bodies of the nociceptors innervating the infected skin. These results gave us some confidence that the approach might be tenable for ongoing pain states, as occurs in some neuropathic and cancer conditions.
All of the foregoing work was performed with micea convenient model for much transgene work. However, before bringing the technology to humans, it was important to consider the species differences that might lead to false conclusions with regard to human applicability. Thus, we decided to test the HSV-enkephalin vector in a non-human primate model. 3 In these experiments, we examined the expression and release of enkephalins in nociceptors as well as the behavioral antihyperalgesic effects that followed the infection of the dorsal surface of one foot of seven Japanese Macaque monkeys. Beginning 2 weeks after applying the HSVenkephalin vector to one foot and HSV-lac-Z vector to the other foot as a control, we tested for capsaicin-induced heat hyperalgesia on the two foot surfaces. As Figure 2 shows, the enkephalin vector produced a robust antihyperalgesic effect, whereas the control vector did not. This test was repeated at 4, 6, 10, 14 and 20 weeks after skin treatment with similar results. Importantly, in the one monkey where the antihyperalgesic effect had diminished substantially, we reapplied the virus-with reestablishment of the antihyperalgesia. As with the mice, the antihyperalgesic effect was reversed by intrathecal injection of the opiate antagonist, naloxone. These results indicated to us that the topical application of this vector would be effective in producing a very prolonged antihyperalgesic effect in non-human primates.
That the observed behavioral effect was mediated by opiates and that this effect was at least partly mediated spinally is indicated by the reversal by intrathecal naloxone. However, we also needed to determine the identity and source of the opiate, and whether and how it was released. Thus, three monkeys were killed at the 6-week point to look for cellular expression of enkephalin peptides. As shown in Figure 3 , enkephalin immunoreactivity was seen in lumbar dorsal root ganglia ipsilateral to skin infection with the HSV. In fact, in this Nomarski optics photomicrograph, it is clear that the enkephalin is vesicular, suggesting packaging in a manner similar to endogenous peptide neurotransmitters. Samples from the HSV-ENK-infected skin were also taken for assessment of evoked release. The skin was placed in a vial containing capsaicin, which activates nociceptors and induces the release of their peptide neurotransmitters (such as substance P and calcitonin gene-related peptide (CGRP)) from releasable pools. The skin samples from the monkeys showed a clear increase in enkephalin release relative to the injury-induced baseline levels, indicating again that the de novo manufactured enkephalins were in releasable pools and could be released by activation of the nociceptors. In addition, spinal cerebrospinal fluid samples taken at the end of the monkeys' testing sessions showed significant ( Â 5) elevation over baseline in leu-enkephalin levels, indicating that the enkephalin could also be released spinally. So, in summary, topical HSV-enkephalin treatment of monkey skin induced the synthesis of vesicularly packaged, activation-evoked releasable pools of enkephalin peptides in nociceptors innervating that skin. The fact that the enkephalins appeared to be released on nociceptor activation is important in that the analgesic effect appears to be use-dependent, whereas constitutive release might be more likely to lead to the development of opiate tolerance. Thus, our monkey study taught us that the peripheral application of the HSV vector induces expression of enkephalins in nociceptors, which when activated release their pools spinally, and in so doing cause a profound, long lasting antihyperalgesia. The fact that these results were observed in a primate lent credence to the possibility of human use.
To this point, all of our work with the HSV-enkephalin vector has investigated cutaneous effects after cutaneous application. In many instances, however, clinical pain syndromes do not arise from the skin. Thus, it was important for us to determine the efficacy of our vector in models of ongoing deeper tissue pain. To this end, we teamed up with the laboratory of Dr Karin Westlund to investigate the efficacy of HSV-enkephalin vector application in rat models of pancreatitis and arthritis. In both an acute model of pancreatitis induced by tail-vein injection of dibutyltin dichloride, as well as a chronic model induced by feeding a high-fat, high-alcohol diet, application of the HSV-enkephalin vector to the surface of the pancreas induced global Met-ENK staining in vesicles of acinar cells in the pancreas, in dorsal root ganglia neurons and in pancreatic afferent termination zones of the spinal cord. In addition, in both of these models, there was an improvement in spontaneous and evoked nociceptive behavior when compared with uninfected animals and animals infected with control (lac-Z vector). Finally, but perhaps most significantly, we observed a robust inhibition of inflammatory cell infiltration as well as destructive inflammation in the pancreas (Figure 4 , from the review by Lu et al. 5 ). This latter finding corresponds with an anti-inflammatory effect of peripherally released enkephalins acting on pancreatic opiate receptors. Thus, these experiments clearly showed that the HSV vector could be applied to deep tissues and have there a profoundly positive effect. Finally, these experiments showed the efficacy of HSV vectors in a third species, rat, indicating the generality of the applicability of this methodology.
With Dr Westlund, we also investigated the efficacy of HSV-enkephalin vector application into knee joints in rats rendered arthritic by intra-articular injection of complete Freund's adjuvant. 6 Compared with arthritic rats treated with HSV-lac-Z, the HSV-ENK-treated arthritic rats had significantly improved nociceptive behavioral responses to mechanical and thermal stimuli. They also had a striking preservation of synovial membrane cytoarchitecture with minimal inflammatory cell infiltrates as well as a decrease in inflammatory biochemical mediators. As with the pancreas, release of enkephalins into the synovium appears to inhibit the inflammatory response, and in so doing protects the tissue and alleviates behavioral hypersensitivity to noxious stimulation.
Taken together these studies present a picture that exceeded our expectations for a herpes gene vector. This attenuated human preproenkephalin vector has shown efficacy in three species and multiple models. It has shown analgesic efficacy in acute and chronic models and profound tissue protective anti-inflammatory effects. And now, a related virus is being tested in humans with cancer pain in a trial led by Dr David Fink of the University of Michigan. 
Gene-silencing vectors
In addition to the potential as an analgesic treatment, HSV vectors can also be quite useful tools for basic science investigations of neural and pharmacological systems. Typically, this means using the vectors to specifically knock down the expression of a particular gene product in sensory neurons to investigate the function of that product. In this, HSV vectors are the equivalent of the lesion studies of old. In addition to allowing specific knockdown of gene products, this approach allows these knockdowns to be performed in adult animals (minimizing the opportunity for compensatory plasticity that occurs in genomic knockouts) and in a regionally specific manner-the viruses only affect neurons to which they are exposed. Incorporating a gene-silencing sequence into an HSV vector, which is then applied to the periphery, acts as a molecular neurosurgical instrument, 'cutting out' a molecule from a particular biochemical chain that is essential for a particular function in a particular cell or cells. To this end, we have used HSV vectors to attenuate expression of neurotransmitters, G-protein-coupled receptors and ion channels. In each case, we have learned something important about the function of these molecules in subserving pain. The first of the gene-silencing vectors that we developed was designed to decrease expression of m-opioid receptors in nociceptors. To understand the importance of developing this vector, it is first necessary to explain some basic pain science. Pain is subserved by two main classes of primary afferent nociceptors: those that are myelinated (Ad fibers) and those that are unmyelinated (C fibers). Ad fibers, when activated, produce a sharp, piercing sensation. Activation of C fibers produces a burning or aching pain. These two fiber types have different anatomical paths, carrying information differentially all the way to the cerebral cortex (which is why they feel different). A corollary of this is that these two fiber types appear to be differentially involved in different types of clinical pain and differentially modulated by analgesic treatments. Thus, for example, C fiber-mediated pain appears to be much more sensitive to the m opioid analgesic morphine than does Ad-mediated pain. However, it was never quite clear where, anatomically, this distinction came about. Thus, we developed an antisense HSV vector to selectively knock down the m-opioid receptor in nociceptors. This vector, which incorporates the complete sequence of the m-opioid receptor gene in reverse orientation relative to the cytomegalovirus promoter, successfully knocked down the receptor in sensory neurons and produced a profound dose-response shift in the analgesic effect of a m-receptor selective agonist. However, this shift was seen only for C fiber-mediated pain responses-not Ad, which is consistent with the Herpes virus-based recombinant herpes vectors DC Yeomans and SP Wilson argument that C fibers have presynaptic opiate receptors, but Ad fibers do not. 7 Another receptor that has been implicated in pain function is the GABA-B receptor. Construction of an antisense HSV vector designed to knock down the expression of this receptor in nociceptors proved critical to understanding a circuit that is involved in the endogenous inhibition of pain. A well-known phenomenon is that causing a mild pain in one area of the body can inhibit pain originating from another. The mechanisms by which this inhibition occurs were not clearly understood, however. One possible mechanism that we decided to investigate involved the near-direct interaction between one set of nociceptors, from one body area, and another. Using our methods of differentially activating different afferent types, we found that repeatedly activating Ad nociceptors innervating one paw and coming from one nerve (saphenous) would inhibit pain responses produced when activating C fibers coming from another nerve (sciatic). 8 That this effect could be blocked by the intrathecal injection of the GABA-B antagonist saclofen suggested that this inhibition might be mediated through spinal GABA-B receptors-but where were these receptors? One possibility was that receptors on the spinal terminals of the C fibers themselves might be the target of GABAergic interneurons that are activated by the incoming Ad barrage. To test this hypothesis, we constructed an antisense HSV using a near-complete sequence of the GABA-B receptor and applied this to the sciatic innervated paw skin of rats. After 2 weeks, we then repeated the Ad activation, but found that the inhibition of the C fiber pain response attenuated significantly, agreeing with the hypothesis that the saphenous Ad activity was activating inhibitory GABA cells, which then released GABA onto the presynaptic terminal of incoming C fibers, inhibiting them by binding to GABA-B receptors. It was clear to us that the approach of using gene-silencing HSV vectors could be quite useful in the dissecting effects of the peripheral nervous system.
Calcitonin gene-related peptide is contained in and released by small-diameter nociceptors. On spinal release, one of the effects of CGRP is to sensitize spinal cord neurons to subsequent nociceptive input and by doing this produce a behavioral hyperalgesia. Therefore, decreasing the release of CGRP from nociceptors should attenuate hyperalgesia. Thus, we constructed an HSV vector encoding antisense to the CGRP gene and applied this to the hindpaw of rats. 9 The vector effectively knocked down expression of CGRP in spinal nociceptor terminals. We also found that infecting dorsal root ganglia neurons in vitro produced a robust knock down of CGRP levels in those cells ( Figure 5 ). Decreasing CGRP expression in nociceptors in vivo significantly attenuated the thermal hyperalgesia normally observed after topical application of capsaicin. The effect of viral Herpes virus-based recombinant herpes vectors DC Yeomans and SP Wilson vector-mediated knockdown of CGRP lasted for 14 weeks after one single application. In this case, the HSV vector-mediated knockdown of CGRP in primary afferent neurons provides a promising tool for studying the mechanisms of chronic pain states, and may also provide a means of treatment for these.
We have also used gene-silencing techniques to investigate ion channels. The first of these involves knockdown of the Nav1.7 sodium channel. 10 The blockade of sodium channels (for example, by lidocaine) has been known for many decades to be an effective means of blocking pain. However, there are nine known varieties of voltage-gated sodium channels in the body, and several of them are found in the membranes of sensory neurons, both nociceptive and non-nociceptive (for example, touch afferents). They are also found in membranes of the muscle efferents of peripheral nerve, as well as in numerous other tissues, such as heart cells and smooth muscles. The 'caines,' such as lidocaine, block them all indiscriminately. The hunt was on therefore to determine which channels, if selectively blocked, would only attenuate pain, without causing numbness, local paralysis and so on. One aspect of pain where sodium channel expression seemed to be upregulated was inflammation. Inflammation typically causes hyperalgesia (for example, when the skin is sunburned). Why are the nociceptors so sensitive? One likely explanation is that there is an upregulation and translocation of sodium channels to the area of inflammation. One channel that had been shown to be upregulated with inflammation was Nav1.7 (formerly PN1). Thus, we constructed an HSV vector incorporating antisense directed toward the gene encoding the Nav1.7 channel. This virus, when applied to the skin prior to the induction with inflammation with complete Freund's adjuvant, completely blocked the upregulation of Nav1.7 Figure 6 Green fluorescent protein (GFP) (first column), Nav1.7 (second column) and merged immunofluorescence (third column) in confocal photomicrographs of dorsal root ganglia from herpes simplex virus (HSV) vector-infected mice. Row 1: GFP-expressing vector; Row 2: GFP and Nav1.7 antisense vector; Row 3: GFP and Nav1.7 antisense vector in CFA-treated mice. Column 3 was derived from pseudocolored overlays of column 1 (green) and column 2 (red). Yellow arrows in second column denote GFP+ neurons.
Herpes virus-based recombinant herpes vectors DC Yeomans and SP Wilson normally seen in the dorsal root ganglia neurons after inflammation ( Figure 6 ). In addition, pretreatment of the skin with this vector completely prevented the development of thermal hyperalgesia after inflammation. These data were the first to show definitively that Nav1.7 channel upregulation was essential for inflammatory hyperalgesia. Subsequently, it was found that this channel seems to be essential for sensing any kind of pain. Thus, this channel has become a major target for pharmaceutical development. It is worth considering, however, whether the further development of an Nav1.7 gene-silencing vector might be a useful therapeutic tool itself.
Another ion channel that appears to be involved in certain types of pain is the acid-sensing ion channel (ASIC) family. One of these, of particular interest to our collaborator, Kathleen Sluka, is ASIC3, which seems to be critical in muscle pain. Thus, Dr Sluka has developed a model of muscle inflammatory pain in mice, wherein she examines the behavioral effects of the injection of an inflammatory mediator into skeletal muscle. One of these effects is the response to muscle injection of a dilute acid, with the idea that this models the lactic acid buildup that occurs with muscle fatigue. This acid injection causes the muscle and the muscle area to become hypersensitive to mechanical stimulation. We found that knock-out mice (ASIC3À/À) were insensitive to this acid injection-they did not become hypersensitive. 11 To take this a step further, we decided to attempt to rescue this function by injecting a recombinant HSV vector that contained the full-length cDNA for the ASIC 3 channel. We found that there was no effect of this vector when it was injected into the skin overlying muscle, but that when the vector was injected into the muscle of ASIC3À/À mice, it restored ASIC3 expression, ASIC3 function in patch electrophysiology experiments, and ASIC3-dependent hypersensitivity after dilute acid muscle injection ( Figure 7) . Thus, in this case, we were able to use the HSV technology to rescue the acid-sensing function muscle afferents in mice that lacked ASIC3 from birth. Thus, this experiment provided definitive information as to the involvement of ASIC3 in muscle pain, and may suggest that ASIC3 could be a target for analgesic drug development.
Conclusion
Herpes simplex virus-based vectors have inherent qualities that make them very attractive for modifying the function of the peripheral nervous system, particularly with regard to pain function. HSV-enkephalin and other HSV vectors have shown robust analgesic and antihyperalgesic effects that are seen in at least three species and over long time periods. The fact that they can be applied in the periphery regionally-that is, to where it hurts-maintains that regional specificity is unique to the herpes system, and uniquely useful. The fact that human trials are underway to determine the utility of HSV vectors in pain speaks to the potential clinical utility of this technology. In addition, HSV vectors provide a unique tool for investigating the mechanisms of the peripheral nervous system. If the intent is to test or validate a potential target for development of treatments for peripheral nerve dysfunction such as pain, the HSV is particularly well suited to the task. 
